ADAGENE INC - ADS, EACH REPRESENTING 1.25
Hinterlegungsschein · US0053291078 · ADAG · A2QN45 (XNAS)
1,99 USD
06.06.2025 19:59
Aktuelle Kurse von ADAGENE INC - ADS, EACH REPRESENTING 1.25
Börse | Ticker | Währung | Letzter Umsatz | Kurs | Tagesveränderung |
---|---|---|---|---|---|
![]() NASDAQ |
ADAG
|
USD
|
06.06.2025 19:59
|
1,99 USD
| 1,76 USD
+13,07 %
|
Performance
Heute | Woche | Monat | 3 Monate | 6 Monate | 1 Jahr | 5 Jahre |
---|---|---|---|---|---|---|
0,00 % | 2,58 % | 24,37 % | -3,86 % | -3,16 % | -33,22 % | -93,36 % |
Firmenprofil zu ADAGENE INC - ADS, EACH REPRESENTING 1.25 Hinterlegungsschein
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Unternehmensdaten
Name ADAGENE INC - ADS, EACH REPRESENTING 1.25
Firma Adagene Inc.
Symbol ADAG
Website
https://www.adagene.com
Heimatbörse
NASDAQ

WKN A2QN45
ISIN US0053291078
Wertpapierart Hinterlegungsschein
Sektor Healthcare
Branche Biotechnology
CEO Dr. Peter P. Luo Ph.D.
Marktkapitalisierung 54 Mio
Land China
Währung USD
Mitarbeiter 0,1 T
Adresse Building C14, 215123 Suzhou
IPO Datum 2021-02-09
Ticker Symbole
Name | Symbol |
---|---|
Frankfurt | 978.F |
NASDAQ | ADAG |
Weitere Aktien
Investoren die ADAGENE INC - ADS, EACH REPRESENTING 1.25 die halten, haben auch folgende Aktien im Depot:
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios.
Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.